Raymond James analyst Lawrence Keusch downgraded Becton Dickinson to Outperform from Strong Buy with a price target of $238, down from $288. In a research note to investors, Keusch says that while Q1 reflected solid momentum with the ability to offset incremental headwinds from coronavirus and price pressure on select products in China, the need to file a comprehensive 510(k) to gain clearance for Alaris large-volume pump software updates will more than likely be an overhang on the stock in the near-term. The analyst continues to see a pathway once past FY20 for a return to 5% sales and 10% EPS growth, 50-100 bp of margin expansion, deleveraging down below 3.0x by calendar year-end 2020 that will enable tuck-in M&A and share repurchase, and says that with the long-term fundamental outlook intact, he maintains a positive view but concede that the stock could be range-bound until there is more certainty on the FDA situation.